ĐÁNH GIÁ HOẠT TÍNH TẾ BÀO GIẾT TỰ NHIÊN Ở BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN TIẾN XA

Abstract

Objective: To evaluate Natural killer cell activity (NKA) and relationship between NKA and clinical and survival characteristics in advanced non-small cell lung cancer patients. Subjects and methods: A prospective, cross-sectional study on 50 advanced NSCLC, treated at Respiratory Center, 103 Military Hospital from January to September 2019; the control groups were 30 stable COPD patients and 30 healthy people. Peripheral blood NKA was determined by the concentration of interferon-gamma secreted in plasma by NK cell after being activated with Promoca ingredient, using NK Vue^TM kit of ATGen, based on ELISA principle. Results: Median NKA values in healthy population, COPD patients and advanced NSCLC patients were 769.5; 280 and 95.6pg/mL, respectively. NKA in NSCLC patients wa significantly lower than that in the other two control group (both p < 0.05). At a cutoff value of NKA at 390pg/mL, the area under the curve was 0.846 (95%CI: 0.763 – 0.928; p = 0.000), with a sensitivity of 74%, a specificity of 87%, a positive predictive value of 90% and a negative predictive value of 67% for the diagnosis of advanced NSCLC. The survival time of patient with NKA < 390pg/mL compared with group with NKA ³ 390pg/mL was 17.24 ± 2.49 versus 21.22 ± 5.65 months (p = 0.285). Conclusions: NKA was reduced in NSCLC and was an immunological marker in diagnosis.